Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

Mouillet, Guillaume; Paillard, Marie-Justine; Maurina, Tristan; Vernerey, Dewi; Nguyen Tan Hon, Thierry; Almotlak, Hamadi; Stein, Ulrich; Calcagno, Fabien; Berthod, Diane; Robert, Elise; Meurisse, Aurelia; Thiery-Vuillemin, Antoine

doi:10.1186/s13063-018-2613-8

Trials

Article metrics
Last updated: Thu, 18 Apr 2024 7:23:45 Z

Open-label, randomized multicentre phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen (dose modification or dose interruptions) in patients with advanced or metastatic renal cell carcinoma: study protocol of the SURF trial

Access & Citations

1555

Article Accesses
5

Web of Science
8

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1745-6215

Contact us

Submission enquiries: Access here and click Contact Us
General enquiries: info@biomedcentral.com